SLNO · Soleno Therapeutics
Acquired Company
Neurocrine Biosciences acquired Soleno Therapeutics on 5/18/2026 for US $53.00 per share in cash, representing a total transaction equity value of about US $2.9 billion.
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. As of May 18, 2026, Soleno Therapeutics, Inc. operates as a subsidiary of Neurocrine Biosciences, Inc.
Market Cap
2.763B
52 Wk Range
$29.43 - $90.32
Previous Close
$53.01
Open
$53.01
Volume
N/A
Day Range
$53.01 - $53.01
Enterprise Value
2.562B
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
1.31%
Institutional Own.
N/A
Qtr Updated
N/A